Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.…
Is Narrower Quarterly Loss Altering The Investment Case For Vor Biopharma Stock?
Vor Biopharma (NASDAQ: VOR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 76 employees.
The shares were at 19.19 USD on 20 November 2026, up 1.2% over 52 weeks. Its 52-week range is 6.500 USD to 26.00 USD: the price is 26.2% below the high and 195.2% above the low.
Its market capitalisation is 1.18B USD.
Vor Biopharma reports return on equity of 423.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 478.74M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 39.00 USD is 103.2% above the current price. The next earnings report is expected on 16 March 2027.